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Introduction
The major cause of cancer mortality is the metastatic spread of
tumor cells that can occur via multiple routes, including the lym-
phatic vasculature. Recent research has indicated that growth of
lymphatic vessels (lymphangiogenesis) in the vicinity of solid
tumors correlates with lymphatic metastasis, and has identified
protein growth factors and receptors, principally vascular
endothelial growth factor C (VEGF-C), VEGF-D, and VEGF
receptor-3 (VEGFR-3), as drivers of lymphangiogenesis. Studies
in animal models and clinicopathological data indicate that these
signaling molecules also contribute to tumor lymphangiogenesis
and metastatic spread. This signaling system is therefore a
promising target for inhibitors of lymphangiogenesis designed to
restrict metastasis. Although most primary tumors are surgically
removed from cancer patients, an antimetastatic approach would
be useful for restricting metastatic spread from inoperable prima-
ry tumors or from remnants of primary tumors that were not com-
pletely removed by surgery. Importantly, this approach could also
be beneficial in restricting further spread from existing cancer
metastases.
Lymphatic vasculature in health and disease
The lymphatic vasculature is essential for homeostasis of tissue
fluid, immune function, and absorption of dietary fat. It maintains
appropriate fluid volume in healthy tissues by transporting
extravasated fluid and macromolecules from tissues to the blood-
stream (Witte et al., 2001).Abnormalities of the lymphatic vascula-
ture that restrict fluid drainage from tissues can be a cause of
lymphedema—a condition that initially presents as a swelling of
the limbs and often becomes debilitating and chronic (Witte et al.,
2001; Alitalo and Carmeliet, 2002; Baldwin et al., 2002). The role
of the lymphatic vasculature in immunity involves entry of antigen-
presenting cells and lymphocytes into blind-ended lymphatic cap-
illaries in the periphery, followed by migration of these cells
through lymphatic vessels to lymph nodes, where they elicit
immune responses.The entry of lymphocytes into lymphatic capil-
laries is made easier by the structural features of these vessels,
which consist of a single thin layer of endothelial cells lacking tight
junctions. Furthermore, the basement membrane of these vessels
is discontinuous, and they are not ensheathed by pericytes or
smooth muscle cells.The endothelial cells of lymphatic capillaries
are attached to the extracellular matrix by elastic fibers (Leak and
Burke, 1966), keeping the vessels open during changes in intersti-
tial pressure (Saharinen et al., 2004). In contrast, larger collecting
lymphatics have perivascular smooth muscle cells with contractile
function to propel lymph fluid within the vessels.
The lymphatic vessels play a major role in cancer biology, as
the spread of tumor cells to lymph nodes implicates the lymphat-
ics as an important route of metastasis and is often an early event
in metastatic disease. The presence of tumor cells in local lymph
nodes is significant for the staging of cancer, hence the relevance
of sentinel lymph node biopsy for planning of therapeutic strate-
gies (Tuttle, 2004) and of sentinel lymphadenectomy as a surgical
approach (Fidler, 1997). However, in some cases, the initial
spread of cancer is not to lymph nodes, indicating that this
process may be complex and that the mechanisms determining
the first sites to develop metastases require further study. It was
long supposed that lymphatic metastasis was a passive process
whereby detached tumor cells reached lymph nodes via drainage
through preexisting local lymphatic vessels. More recently, it has
become apparent that lymphangiogenesis can contribute actively
to metastasis.
Detection of lymphatics
Analysis of lymphatic vessels in cancer was hampered by a lack
of markers that discriminated between lymphatics and blood ves-
sels. This changed recently with discovery of improved markers
such as the transcription factor Prox-1, which is essential for lym-
phatic development (Wigle et al., 2002; Alitalo and Carmeliet,
2002), is a determinant of lymphatic endothelial cell (LEC) phe-
notype (Figure 1) (for review see Oliver, 2004), and is a useful
marker for LECs in human tissues (Wilting et al., 2002).
Podoplanin is a glomerular podocyte membrane mucoprotein
expressed by LECs (Breiteneder-Geleff et al., 1999) that is
required for lymphatic development and promotes endothelial cell
adhesion, migration, and tube formation (Schacht et al., 2003).
Although expressed in some nonendothelial cell types,
podoplanin is not expressed in blood vessels and is a useful
marker of small lymphatics. The lymphatic vessel hyaluronan
receptor 1 (LYVE-1) is a homolog of CD44 expressed by embry-
onic and adult lymphatics (Prevo et al., 2001). Although
expressed by liver and spleen sinusoids and macrophages, it has
been a useful marker of lymphatics in mouse and man.VEGFR-3
(also known as Flt4) is a cell surface receptor tyrosine kinase that
signals for lymphangiogenesis and is predominantly expressed
on lymphatic endothelium in adult tissues but also detected on
some fenestrated blood vessels (Partanen et al., 2000). Its utility
as a marker for lymphatics in cancer is limited because of upreg-
ulation on some tumor blood vessels (Valtola et al., 1999).
Antibodies to podoplanin, LYVE-1, and VEGFR-3 have facili-
tated separation of LECs from blood vascular endothelial cells
using magnetic beads or flow cytometry (for review, see Pepper
and Skobe, 2003). Cultures of pure LECs allow in vitro analysis of
this cell type for signaling that controls cell proliferation, differenti-
ation, and cell adhesion (Mäkinen et al., 2001). Further, the phe-
notype of these cells can be compared to blood vascular
endothelium by DNA array (Petrova et al., 2002; Podgrabinska et
al., 2002; Hirakawa et al., 2003; Pepper and Skobe, 2003) or pro-
teomic technologies which will surely identify more markers spe-
cific for blood vessels or lymphatics and indicate novel
approaches for targeting therapeutics to these vessels in tumors.
Signaling for lymphangiogenesis
The best characterized lymphangiogenic growth factors are
VEGF-C and VEGF-D, secreted glycoproteins that activate
VEGFR-3 (Joukov et al., 1996; Achen et al., 1998), a receptor
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expressed on lymphatic endothelium in adults (Lymboussaki et
al., 1998). VEGFR-3 activation induces proliferation of LECs in
vitro (Mäkinen et al., 2001) and lymphangiogenesis in vivo
(Veikkola et al., 2001). Conversely, some human hereditary lym-
phedemas are associated with missense VEGFR-3 mutations
which inactivate the tyrosine kinase domain and impair signaling
(Karkkainen et al., 2000). Likewise, expression of a soluble form
of VEGFR-3 that sequesters VEGF-C and VEGF-D in transgenic
mice inhibits lymphangiogenesis and induces lymphedema
(Mäkinen et al., 2001). Inactivation of the Vegfr-3 gene in mice
demonstrated that it also plays a role in formation of blood ves-
sels, before emergence of the lymphatics (Dumont et al., 1998).
Inactivation of the gene for neuropilin-2, a
cell surface receptor that binds VEGF-C
and may be a VEGFR-3 coreceptor
(Karkkainen et al., 2001), causes abnor-
mal lymphatic vessel development (Yuan
et al., 2002), further emphasizing the
importance of VEGF-C/VEGFR-3 signal-
ing for lymphangiogenesis (Figure 1).
Human VEGF-C and VEGF-D also
activate VEGFR-2 (known as Flk1 in
mouse; KDR in man) (Joukov et al., 1996;
Achen et al., 1998), a receptor expressed
on the endothelium of blood vessels that
is thought to signal for angiogenesis,
although it can be expressed on lymphat-
ics (Saaristo et al., 2002). VEGF-C and
VEGF-D are initially secreted in full-
length forms that appear to activate
VEGFR-3 but not VEGFR-2; however,
upon proteolytic processing, they are
converted to mature forms that bind both
VEGFR-2 and VEGFR-3 with high affinity
(Joukov et al., 1997; Stacker et al., 1999).
Recent in vitro studies have demonstrat-
ed that the serine protease plasmin
(McColl et al., 2003) and members of the
proprotein convertase family (Siegfried et
al., 2003) are able to proteolytically
process VEGF-C and VEGF-D. The
receptor binding affinities explain why
full-length VEGF-C and VEGF-D are pre-
dominantly lymphangiogenic (Jeltsch et
al., 1997; Enholm et al., 2001; Rissanen
et al., 2003), whereas the mature forms
induce growth of both blood vessels and
lymphatics (Cao et al., 1998; Byzova et
al., 2002; Rissanen et al., 2003).
The function of VEGF-C and VEGF-D
has been explored in numerous animal models. Ablation of the
mouse Vegf-c gene showed that it is essential for emergence of
the first lymphatic vessels from the cardinal vein during embryo-
genesis (Karkkainen et al., 2004), whereas the Vegf-d gene does
not play a crucial role in embryonic lymphatic vessel development
(Baldwin et al., 2005). Full-length VEGF-C and VEGF-D, and a
VEGFR-3-specific mutant of VEGF-C (VEGF-C156S) (Joukov et
al., 1998), induced predominantly lymphangiogenesis in rabbit
hindlimb muscle (Rissanen et al., 2003), whereas mature VEGF-
D induced both angiogenesis and lymphangiogenesis, suggest-
ing that different forms of these proteins may find application for
therapeutic angiogenesis or lymphangiogenesis (Alitalo and
F O C U S
Figure 1. Development of lymphatic vessels in
embryogenesis and cancer
Some of the proteins that are important in these
events are shown underneath each section.
Arrows denote the direction of lymph flow in the
lymphatic vessels. A more extensive review of
these processes with full lists of supporting refer-
ences is presented elsewhere (Baldwin et al.,
2002; Oliver, 2004). A recent report has called
into question the involvement of LEC precursors
in tumor lymphangiogenesis (He et al., 2004b).
The role of FOXC2 has recently been delineated
(Petrova et al., 2004).
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Carmeliet, 2002). Indeed, administration of VEGF-C promotes
lymphangiogenesis in animal models of lymphedema that may
ameliorate the condition (for example, see Szuba et al., 2002),
and VEGF-C gene therapy restores lymph flow across incision
wounds (Saaristo et al., 2004), suggesting approaches for reduc-
ing tissue edema in skin and muscle flaps generated during
reconstructive surgery. Further, adenoviral delivery of mature
VEGF-D induced transmural angiogenesis and increased
myocardial perfusion in porcine heart (Rutanen et al., 2004).
Little is known about intracellular lymphangiogenic signaling.
VEGFR-3 induces the phosphoinositide 3-kinase pathway lead-
ing to Akt activation, and the mitogen-activated protein kinase
pathway, including activation of p42/p44 kinases, probably by
protein kinase C (Mäkinen et al., 2001). However, signaling that
controls specific events in lymphangiogenesis, e.g., tube forma-
tion, remains uncharacterized.
Other growth factors have been reported as lymphangio-
genic, namely VEGF-A (Nagy et al., 2002), FGF-2 (Kubo et al.,
2002), and PDGF-BB (Cao et al., 2004). The lymphangiogenic
effect of FGF-2 appears to be indirect, i.e., via VEGF-C or VEGF-
D. VEGF-A may induce lymphangiogenesis directly by signaling
via VEGFR-2 on LECs; however, an indirect mechanism depen-
dent on VEGF-C or VEGF-D could be responsible. In one recent
report, PDGF-BB was observed to induce motility of isolated
LECs and lymphangiogenesis in mouse cornea in vivo (Cao et
al., 2004). Interestingly, the lymphangiogenesis induced by
PDGF-BB could not be restricted by inhibitors blocking interac-
tion of VEGF-C or VEGF-D with VEGFR-3, suggesting that, in this
model, PDGF-BB exerts its effect via an independent pathway
that may involve PDGF receptors on lymphatic vessels (Cao et
al., 2004). Nevertheless, it is still possible that activation of PDGF
receptors could lead to activation of VEGFR-3 in LECs by intra-
cellular mechanisms. The importance of PDGF signaling for lym-
phangiogenesis during embryogenesis is unknown. Finally, the
secreted protein angiopoietin-2 (Ang-2), a ligand for the Tie2
receptor tyrosine kinase, is critical for establishing the lymphatic
vasculature, as mutant mice deficient for Ang-2 have defects in
lymphatic organization and smooth muscle association, although
the mice do possess peripheral lymphatics (Gale et al., 2002).
Comparison with Vegf-c-deficient mice suggests that VEGF-
C/VEGFR-3 signaling is a key primary proliferation pathway for
lymphatic vessels, whereas Ang-2 is important in later remodel-
ing stages (Figure 1) (Gale et al., 2002; Karkkainen et al., 2004).
Role of lymphangiogenesis in cancer
The existence of functional intratumoral lymphatics in human
cancer was doubted, because lymphatic vessels might not pen-
etrate into expanding primary tumors due to the physical pres-
sure inside tumors (Padera et al., 2002). Furthermore, it was
envisaged that lymphangiogenesis was not required to explain
lymphatic metastasis, as tumor cells might spread via preexist-
ing lymphatic vessels (Pepper, 2001). However, intratumoral
lymphatics and lymphangiogenesis were recently detected in
head and neck cancer, thyroid carcinoma, and melanoma, and
may contribute to lymph node metastasis (Beasley et al., 2002;
Hall et al., 2003; Straume et al., 2003). Moreover, peritumoral
lymphatics located immediately adjacent to tumors or in the per-
itumoral stroma, which can be dilated or enlarged, are known to
be associated with human tumors (Pepper, 2001; Dadras et al.,
2004; Bono et al., 2004).
Experimental models of tumor lymphangiogenesis
Studies in animal models have indicated the important role of
VEGF-C/VEGF-D/VEGFR-3 lymphangiogenic signaling in
tumor biology (Figure 1). For example, VEGF-C induced intratu-
moral lymphangiogenesis when expressed in human breast
cancer cells orthotopically transplanted onto nude mice that
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Table 1. Inhibitors of the VEGF-C/VEGF-D/VEGFR-3 lymphangiogenic signaling pathway
Inhibitor Class of compound Target1 Clinical trial status2 Reference
Soluble VEGFR-3 Ig fusion protein VEGF-C, VEGF-D, and any Not in clinical trial Karpanen et al., 2001; 
unknown VEGFR-3 ligands He et al., 2002;
Krishnan et al., 2003
VEGF-D antibody Monoclonal antibody VEGF-D Not in clinical trial Achen et al., 2000;
Stacker et al., 2001
VEGFR-3 antibody Monoclonal antibody VEGFR-3 EC3 Not in clinical trial Kubo et al., 2000; 
Persaud et al., 2004
BAY 43-9006 (Sorafenib) Bi-aryl urea VEGFR-3 TK4, VEGFR-2 TK, Phase III for renal cell cancer; Phase II for Wilhelm et al., 2004
Raf-1 S/TK4, PDGFR-β TK, c-Kit TK, CML and prostate, ovarian, pancreatic,
Flt3 TK, FGFR-1 TK, BRAF S/TK head and neck, breast, thyroid, and 
lung cancers; Phase I for glioma
CEP-7055 N,N-dimethyl glycine ester VEGFR-3 TK, VEGFR-2 TK, Phase I for various malignancies Ruggeri et al., 2003
VEGFR-1 TK, Flt3 TK, 
Mlk1 S/TK, Mlk3 S/TK
MAE87, MAE106, MAZ51 Indolinone VEGFR-3 TK, VEGFR-2 TK Not in clinical trial Kirkin et al., 2001
PTK787/ZK 222584 Chloroanilino-pyridylmethyl VEGFR-3 TK, VEGFR-2 TK, Phase III for colorectal cancer; Phase II Lin et al., 2002
(Vatalanib) phthalazine succinate VEGFR-1 TK, c-Kit TK, for mesothelioma and myelodysplastic 
c-Fms TK, PDGFR-β TK syndromes; Phase I and II for CML, AML, 
and AMM
1Some of the inhibitors also target kinases that are not involved in lymphangiogenic signaling.  For the small molecule inhibitors, targets or groups of targets
that these compounds were initially designed or screened to inhibit are underlined.  VEGF-A, FGF-2, and PDGF-BB have been reported to induce lymphan-
giogenesis in various models, but these targets are not included here, as their mechanisms of action in lymphangiogenesis have yet to be fully delineated.
2These trials are either active, or approved but not yet active, as cited on the Cancer Trials page of the website of the National Cancer Institute
(http://www.cancer.gov/clinicaltrials),  with the exception of the CEP-7055 trials that are referred to elsewhere (Ruggeri et al., 2003).
3EC denotes extracellular domain.
4TK denotes protein tyrosine kinase, and S/TK denotes protein serine/threonine kinase.
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resulted in enhanced metastasis to regional lymph nodes and to
the lung (Skobe et al., 2001b). In similar breast cancer models,
VEGF-C promoted growth of tumor-associated lymphatics,
commonly infiltrated with tumor cells (Karpanen et al., 2001),
and metastatic spread to local lymph nodes (Mattila et al.,
2002). In a transgenic mouse model system, animals overex-
pressing VEGF-C in β cells of the pancreas exhibited extensive
lymphangiogenesis around the endocrine islets of Langerhans,
in contrast to wild-type controls (Mandriota et al., 2001). When
tumors were induced in these islets, tumor cells entered sur-
rounding lymphatics and established metastases in draining
lymph nodes, in contrast to tumors of mice lacking the VEGF-C
transgene, which did not metastasize.
VEGF-D promoted formation of intratumoral lymphatics and
metastasis to lymph nodes in a mouse tumor xenograft model
(Stacker et al., 2001). It also enhanced tumor angiogenesis and
solid tumor growth that may reflect proteolytic processing to
mature VEGF-D capable of activating VEGFR-2 and signaling
for angiogenesis. The enhanced metastasis induced by VEGF-
D in this model could be blocked by a neutralizing antibody tar-
geting the central domain of VEGF-D (Stacker et al., 2001), the
first direct evidence for the prevention of lymphatic metastasis in
a tumor model (Jain and Padera, 2002). VEGF-C also induced
tumor angiogenesis, and lymphangiogenesis, when human
melanoma cells were transplanted onto nude mice (Skobe et
al., 2001a). Use of blocking VEGFR-2 antibodies suggested that
VEGF-C signaling for tumor angiogenesis is via VEGFR-2
(Kadambi et al., 2001). Nevertheless, a role for VEGFR-3 in
tumor blood vessels is possible, as it can be upregulated in
blood vessels in human cancer (Valtola et al., 1999), and a
blocking antibody to VEGFR-3 suppressed tumor growth in a
mouse model by inhibiting angiogenesis and inducing microhe-
morrhage in the tumors (Kubo et al., 2000).
Despite the presence of intratumoral lymphatics in some of
the models above, other VEGF-C models suggested that these
lymphatics are not functional, and that lymphatics in the tumor
margin alone are sufficient for lymphatic metastasis (Padera et
al., 2002). Irrespective of the importance of lymphatic vessel
location for metastasis, lymph node metastasis can certainly be
suppressed by inhibitors of lymphangiogenic signaling such as
a soluble form of VEGFR-3 (Karpanen et al., 2001; He et al.,
2002; Krishnan et al., 2003) or a monoclonal antibody to VEGF-
D (Stacker et al., 2001). The findings that VEGF-C and VEGF-D
can promote tumor angiogenesis suggest that targeting these
proteins in cancer may bring the double benefit of restricting
growth of blood vessels and lymphatics.
A recent study suggested that PDGF-BB may promote lym-
phangiogenesis in cancer. Expression of PDGF-BB in murine
fibrosarcoma cells induced tumor lymphangiogenesis in syn-
geneic mice, causing formation of intratumoral lymphatics and
enhanced metastasis in lymph nodes (Cao et al., 2004). PDGF-
BB also promoted tumor angiogenesis and solid tumor growth
in this model.
Clinicopathological findings
Expression of VEGF-C or VEGF-D correlates with lymphatic
metastasis in a range of human cancers, whereas involvement of
PDGF-BB is poorly characterized. This topic has been reviewed
extensively (Stacker et al., 2002a, 2002b; He et al., 2004a), and
so is discussed here only briefly. Many studies indicate that
VEGF-C levels in primary tumors correlate with lymph node
metastasis in thyroid, prostate, gastric, colorectal, lung, and
esophageal carcinomas (for review, see Stacker et al., 2002a).
Moreover, patients with gastric cancers expressing high levels of
VEGF-C were reported to have poorer prognoses than those with
tumors expressing low levels of VEGF-C (Yonemura et al., 1999).
Similarly, VEGF-C has been reported as a potential prognostic
factor in cervical and ovarian carcinomas (Ueda et al., 2002;
Nishida et al., 2004). Analysis of VEGF-D suggests that it also
promotes metastasis in human cancer.VEGF-D has been report-
ed as an independent prognostic marker for disease-free and
overall survival in colorectal carcinoma that correlates with lym-
phatic involvement (White et al., 2002). Expression of VEGF-D
and VEGFR-3 in endometrial carcinoma may predict myometrial
invasion and lymph node metastasis, and may prospectively
identify patients at increased risk for poor outcome (Yokoyama et
al., 2003a). Furthermore, VEGF-D was found to be an indepen-
dent predictor of poor outcome in epithelial ovarian carcinoma
(Yokoyama et al., 2003b) and to be elevated in primary prostate
tumors with sentinel lymph node involvement compared to those
lacking lymph node involvement (Stearns et al., 2004). In a minor-
ity of studies, expression of VEGF-C or VEGF-D did not correlate
with lymphatic involvement or cancer progression (for review, see
Stacker et al., 2002b); for example, VEGF-D mRNA was found to
be downregulated in breast cancer tissue and inversely correlat-
ed with lymph node metastasis (Koyama et al., 2003). However,
in another study, VEGF-D protein was reported to be upregulated
in breast cancer and to correlate with lymph node metastasis and
poor patient prognosis (Nakamura et al., 2003).
Tumor lymphangiogenesis as a therapeutic target
The findings from experimental models of lymphatic metastasis
and clinicopathological analyses of human cancer identify the
VEGF-C/VEGF-D/VEGFR-3 lymphangiogenic signaling path-
way as a target for anticancer therapeutics designed to limit
metastatic spread. The observations that VEGF-C and VEGF-D
can also promote tumor angiogenesis make targeting these
molecules more attractive, particularly in light of the clinical suc-
cess with bevacizumab (also known as Avastin), an inhibitory
monoclonal antibody to the angiogenic protein VEGF-A, for
enhancing survival in patients with metastatic colorectal cancer
(Hurwitz et al., 2004).
Numerous strategies could be used to inhibit this lymphan-
giogenic signaling pathway (Table 1), including blocking the pro-
teolytic activation of VEGF-C and VEGF-D or blocking the binding
of VEGF-C or VEGF-D to VEGFR-2 and VEGFR-3 with neutraliz-
ing antibodies against the ligands or the receptors. Neutralizing
antibodies to VEGF-D (Achen et al., 2000; Stacker et al., 2001),
VEGFR-2 (Bocci et al., 2004) and VEGFR-3 (Kubo et al., 2000;
Persaud et al., 2004) have been reported. Alternatively, this could
be achieved with soluble versions of the receptors (Karpanen et
al., 2001; He et al., 2002; Krishnan et al., 2003). A third strategy
includes blocking the tyrosine kinase activity of VEGFR-2 and
VEGFR-3 using orally active small molecule inhibitors that enter
the cell; small molecules inhibiting both VEGFR-2 and VEGFR-3
include BAY 43-9006 (Wilhelm et al., 2004), CEP-7055 (Ruggeri
et al., 2003), and PTK787/ZK222584 (Lin et al., 2002), although
these compounds are not specific, as they inhibit multiple other
kinases (Table 1). Irrespective of the approach, it will be important
to identify appropriate cohorts of cancer patients to allow effects
on metastatic spread to be monitored.
Concluding remarks
Important questions remain regarding the role of lymphatic ves-
sels and lymphangiogenesis in metastasis. Debate continues as
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to the relative contribution of intratumoral and peritumoral lym-
phatics to this process. It is not known if enlargement of preexist-
ing lymphatics in the tumor periphery is sufficient, or if formation
of new lymphatics is required to promote lymphatic metastasis.
Recently, it has been speculated that, in addition to stimulating
growth of tumor lymphatics, VEGF-C and VEGF-D might con-
tribute to metastasis by altering the permeability or cell adhesive
properties of lymphatic endothelium; in vitro analyses of LECs
may shed light on this. The importance of other potential lym-
phangiogenic growth factors, in particular members of the
angiopoietin and PDGF families, for metastatic spread of human
cancer is unknown. Despite these uncertainties, there is abun-
dant evidence from experimental and clinicopathological studies
to justify targeting the VEGF-C/VEGF-D/VEGFR-3 lymphangio-
genic signaling pathway in the clinic.This will be a priority for the
future.
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